RPRX
What one share of Royalty Pharma holds
Pharmaceutical Preparations
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
Royalty Pharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.54 |
|---|---|
| Profit | $1.87 |
| Cash and investments | $1.82 |
| Debt | $20.14 |
| Book value | $21.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $5.65 | $1.32 | — | $5.42 | $0.30 | $26.36 |
| 2021 | $5.52 | $1.49 | — | $4.86 | $0.68 | $24.71 |
| 2022 | $5.11 | $0.10 | — | $4.90 | $0.76 | $21.75 |
| 2023 | $3.91 | $2.53 | — | $4.96 | $0.80 | $22.53 |
| 2024 | $3.81 | $1.91 | — | $4.66 | $0.84 | $23.08 |
| 2025 | $4.21 | $1.78 | — | $4.41 | — | $22.60 |